Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) Stock Competitors & Peer Comparison

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, VRTX has a market cap of 131.9B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while VRTX trades at $519.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas VRTX's P/E ratio is 27.31. In terms of profitability, DNA-WT's ROE is -0.60%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, DNA-WT is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check VRTX's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, REGN has a market cap of 81.8B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while REGN trades at $793.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas REGN's P/E ratio is 17.40. In terms of profitability, DNA-WT's ROE is -0.60%, compared to REGN's ROE of +0.14%. Regarding short-term risk, DNA-WT is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check REGN's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas VRNA's P/E ratio is -102.80. In terms of profitability, DNA-WT's ROE is -0.60%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, DNA-WT is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check VRNA's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ARGX has a market cap of 61.6B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ARGX trades at $990.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas ARGX's P/E ratio is 89.40. In terms of profitability, DNA-WT's ROE is -0.60%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, DNA-WT is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check ARGX's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, MRNA has a market cap of 58.2B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while MRNA trades at $146.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas MRNA's P/E ratio is -18.00. In terms of profitability, DNA-WT's ROE is -0.60%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, DNA-WT is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check MRNA's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RVMDW has a market cap of 44.5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while RVMDW trades at $11.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas RVMDW's P/E ratio is -1.29. In terms of profitability, DNA-WT's ROE is -0.60%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, DNA-WT is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check RVMDW's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RVMD has a market cap of 43.6B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while RVMD trades at $205.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas RVMD's P/E ratio is -23.26. In terms of profitability, DNA-WT's ROE is -0.60%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, DNA-WT is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check RVMD's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas SGEN's P/E ratio is -57.19. In terms of profitability, DNA-WT's ROE is -0.60%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, DNA-WT is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check SGEN's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ONC has a market cap of 37.8B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ONC trades at $353.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas ONC's P/E ratio is 62.29. In terms of profitability, DNA-WT's ROE is -0.60%, compared to ONC's ROE of +0.14%. Regarding short-term risk, DNA-WT is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check ONC's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ALNY has a market cap of 33.5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ALNY trades at $249.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas ALNY's P/E ratio is 45.04. In terms of profitability, DNA-WT's ROE is -0.60%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, DNA-WT is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check ALNY's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ROIV has a market cap of 29.6B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ROIV trades at $41.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas ROIV's P/E ratio is -39.02. In terms of profitability, DNA-WT's ROE is -0.60%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, DNA-WT is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check ROIV's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, INSM has a market cap of 27.2B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while INSM trades at $125.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas INSM's P/E ratio is -30.49. In terms of profitability, DNA-WT's ROE is -0.60%, compared to INSM's ROE of -1.11%. Regarding short-term risk, DNA-WT is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check INSM's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, BNTX has a market cap of 24.8B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while BNTX trades at $98.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas BNTX's P/E ratio is -12.82. In terms of profitability, DNA-WT's ROE is -0.60%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, DNA-WT is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check BNTX's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, INCY has a market cap of 24.8B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while INCY trades at $122.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas INCY's P/E ratio is 16.42. In terms of profitability, DNA-WT's ROE is -0.60%, compared to INCY's ROE of +0.30%. Regarding short-term risk, DNA-WT is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check INCY's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, UTHR has a market cap of 21.3B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while UTHR trades at $502.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas UTHR's P/E ratio is 17.99. In terms of profitability, DNA-WT's ROE is -0.60%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, DNA-WT is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check UTHR's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas BGNE's P/E ratio is -22.55. In terms of profitability, DNA-WT's ROE is -0.60%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, DNA-WT is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check BGNE's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, GMAB has a market cap of 20B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while GMAB trades at $32.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas GMAB's P/E ratio is 24.60. In terms of profitability, DNA-WT's ROE is -0.60%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, DNA-WT is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check GMAB's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ASND has a market cap of 16.5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ASND trades at $264.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas ASND's P/E ratio is -109.47. In terms of profitability, DNA-WT's ROE is -0.60%, compared to ASND's ROE of +1.90%. Regarding short-term risk, DNA-WT is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check ASND's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, NBIX has a market cap of 15.8B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while NBIX trades at $157.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas NBIX's P/E ratio is 22.72. In terms of profitability, DNA-WT's ROE is -0.60%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, DNA-WT is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check NBIX's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, JAZZ has a market cap of 15.4B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while JAZZ trades at $245.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas JAZZ's P/E ratio is 9.17. In terms of profitability, DNA-WT's ROE is -0.60%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, DNA-WT is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check JAZZ's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, SMMT has a market cap of 14.7B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while SMMT trades at $18.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas SMMT's P/E ratio is -16.45. In terms of profitability, DNA-WT's ROE is -0.60%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, DNA-WT is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check SMMT's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, BBIO has a market cap of 14.2B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while BBIO trades at $72.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas BBIO's P/E ratio is -19.35. In terms of profitability, DNA-WT's ROE is -0.60%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, DNA-WT is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check BBIO's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, EXEL has a market cap of 14.1B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while EXEL trades at $56.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas EXEL's P/E ratio is 16.06. In terms of profitability, DNA-WT's ROE is -0.60%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, DNA-WT is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check EXEL's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, BMRN has a market cap of 12.8B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while BMRN trades at $66.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas BMRN's P/E ratio is 31.93. In terms of profitability, DNA-WT's ROE is -0.60%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, DNA-WT is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check BMRN's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, HALO has a market cap of 12.8B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while HALO trades at $107.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas HALO's P/E ratio is 20.14. In terms of profitability, DNA-WT's ROE is -0.60%, compared to HALO's ROE of +1.81%. Regarding short-term risk, DNA-WT is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check HALO's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas KRTX's P/E ratio is -28.09. In terms of profitability, DNA-WT's ROE is -0.60%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, DNA-WT is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check KRTX's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, MDGL has a market cap of 12.5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while MDGL trades at $540.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas MDGL's P/E ratio is -42.19. In terms of profitability, DNA-WT's ROE is -0.60%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, DNA-WT is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check MDGL's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ARWR has a market cap of 11.4B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ARWR trades at $80.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas ARWR's P/E ratio is -35.85. In terms of profitability, DNA-WT's ROE is -0.60%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, DNA-WT is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check ARWR's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while TECH trades at $72.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas TECH's P/E ratio is 37.25. In terms of profitability, DNA-WT's ROE is -0.60%, compared to TECH's ROE of +0.09%. Regarding short-term risk, DNA-WT is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check TECH's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas RNAM's P/E ratio is -17.39. In terms of profitability, DNA-WT's ROE is -0.60%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, DNA-WT is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check RNAM's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, AXSM has a market cap of 11.1B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while AXSM trades at $216.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas AXSM's P/E ratio is -56.55. In terms of profitability, DNA-WT's ROE is -0.60%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, DNA-WT is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check AXSM's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, KRYS has a market cap of 10B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while KRYS trades at $340.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas KRYS's P/E ratio is 42.61. In terms of profitability, DNA-WT's ROE is -0.60%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, DNA-WT is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check KRYS's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas RXDX's P/E ratio is -56.47. In terms of profitability, DNA-WT's ROE is -0.60%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, DNA-WT is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check RXDX's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, PTGX has a market cap of 9.5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while PTGX trades at $147.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas PTGX's P/E ratio is 143.48. In terms of profitability, DNA-WT's ROE is -0.60%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, DNA-WT is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check PTGX's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, KYMR has a market cap of 9.4B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while KYMR trades at $114.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas KYMR's P/E ratio is -35.82. In terms of profitability, DNA-WT's ROE is -0.60%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, DNA-WT is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check KYMR's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, PRAX has a market cap of 9.2B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while PRAX trades at $330.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas PRAX's P/E ratio is -25.58. In terms of profitability, DNA-WT's ROE is -0.60%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, DNA-WT is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check PRAX's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas NUVL's P/E ratio is -21.79. In terms of profitability, DNA-WT's ROE is -0.60%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, DNA-WT is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check NUVL's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CYTK has a market cap of 9B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while CYTK trades at $72.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas CYTK's P/E ratio is -10.03. In terms of profitability, DNA-WT's ROE is -0.60%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, DNA-WT is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check CYTK's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while CRNX trades at $84.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas CRNX's P/E ratio is -16.86. In terms of profitability, DNA-WT's ROE is -0.60%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, DNA-WT is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check CRNX's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, TXG has a market cap of 8.9B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while TXG trades at $70.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas TXG's P/E ratio is -118.83. In terms of profitability, DNA-WT's ROE is -0.60%, compared to TXG's ROE of -0.09%. Regarding short-term risk, DNA-WT is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check TXG's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, IBRX has a market cap of 8.8B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while IBRX trades at $8.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas IBRX's P/E ratio is -8.63. In terms of profitability, DNA-WT's ROE is -0.60%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, DNA-WT is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check IBRX's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas IMGN's P/E ratio is -111.55. In terms of profitability, DNA-WT's ROE is -0.60%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, DNA-WT is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check IMGN's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, PCVX has a market cap of 8.6B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while PCVX trades at $59.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas PCVX's P/E ratio is -7.80. In terms of profitability, DNA-WT's ROE is -0.60%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, DNA-WT is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check PCVX's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, IONS has a market cap of 8.5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while IONS trades at $51.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas IONS's P/E ratio is -29.91. In terms of profitability, DNA-WT's ROE is -0.60%, compared to IONS's ROE of -1.11%. Regarding short-term risk, DNA-WT is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check IONS's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, TWST has a market cap of 8.4B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while TWST trades at $134.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas TWST's P/E ratio is -60.70. In terms of profitability, DNA-WT's ROE is -0.60%, compared to TWST's ROE of -0.30%. Regarding short-term risk, DNA-WT is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check TWST's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas BPMC's P/E ratio is -51.58. In terms of profitability, DNA-WT's ROE is -0.60%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, DNA-WT is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check BPMC's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while APGE trades at $135.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas APGE's P/E ratio is -31.19. In terms of profitability, DNA-WT's ROE is -0.60%, compared to APGE's ROE of -0.30%. Regarding short-term risk, DNA-WT is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check APGE's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ABVX has a market cap of 8.3B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ABVX trades at $113.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas ABVX's P/E ratio is -59.54. In terms of profitability, DNA-WT's ROE is -0.60%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, DNA-WT is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check ABVX's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, TGTX has a market cap of 8.3B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while TGTX trades at $54.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas TGTX's P/E ratio is 19.57. In terms of profitability, DNA-WT's ROE is -0.60%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, DNA-WT is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check TGTX's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas CERE's P/E ratio is -16.47. In terms of profitability, DNA-WT's ROE is -0.60%, compared to CERE's ROE of -0.72%. Regarding short-term risk, DNA-WT is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check CERE's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, SYRE has a market cap of 7.9B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while SYRE trades at $90.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas SYRE's P/E ratio is -46.56. In terms of profitability, DNA-WT's ROE is -0.60%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, DNA-WT is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check SYRE's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, IMVT has a market cap of 7.8B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while IMVT trades at $37.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas IMVT's P/E ratio is -13.35. In terms of profitability, DNA-WT's ROE is -0.60%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, DNA-WT is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check IMVT's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas MTSR's P/E ratio is -23.58. In terms of profitability, DNA-WT's ROE is -0.60%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, DNA-WT is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check MTSR's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CAI has a market cap of 7.4B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while CAI trades at $26.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas CAI's P/E ratio is 73.19. In terms of profitability, DNA-WT's ROE is -0.60%, compared to CAI's ROE of +0.19%. Regarding short-term risk, DNA-WT is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check CAI's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RYTM has a market cap of 7B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while RYTM trades at $102.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas RYTM's P/E ratio is -32.94. In terms of profitability, DNA-WT's ROE is -0.60%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, DNA-WT is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check RYTM's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, BLTE has a market cap of 6.9B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while BLTE trades at $173.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas BLTE's P/E ratio is -92.51. In terms of profitability, DNA-WT's ROE is -0.60%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, DNA-WT is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check BLTE's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas MRUS's P/E ratio is -17.05. In terms of profitability, DNA-WT's ROE is -0.60%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, DNA-WT is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check MRUS's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas ACLX's P/E ratio is -28.27. In terms of profitability, DNA-WT's ROE is -0.60%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, DNA-WT is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check ACLX's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas RETA's P/E ratio is -66.29. In terms of profitability, DNA-WT's ROE is -0.60%, compared to RETA's ROE of +0.47%. Regarding short-term risk, DNA-WT is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check RETA's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CGON has a market cap of 6.5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while CGON trades at $73.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas CGON's P/E ratio is -27.43. In terms of profitability, DNA-WT's ROE is -0.60%, compared to CGON's ROE of -0.25%. Regarding short-term risk, DNA-WT is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check CGON's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas CNTA's P/E ratio is -22.63. In terms of profitability, DNA-WT's ROE is -0.60%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, DNA-WT is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check CNTA's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, SRRK has a market cap of 6.2B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while SRRK trades at $51.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas SRRK's P/E ratio is -15.03. In terms of profitability, DNA-WT's ROE is -0.60%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, DNA-WT is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check SRRK's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, TVTX has a market cap of 6.1B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while TVTX trades at $65.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas TVTX's P/E ratio is -146.20. In terms of profitability, DNA-WT's ROE is -0.60%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, DNA-WT is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check TVTX's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, DNTH has a market cap of 6B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while DNTH trades at $107.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas DNTH's P/E ratio is -25.95. In terms of profitability, DNA-WT's ROE is -0.60%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, DNA-WT is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check DNTH's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, MIRM has a market cap of 5.9B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while MIRM trades at $96.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas MIRM's P/E ratio is -6.65. In terms of profitability, DNA-WT's ROE is -0.60%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, DNA-WT is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check MIRM's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ORKA has a market cap of 5.8B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ORKA trades at $95.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas ORKA's P/E ratio is -49.48. In terms of profitability, DNA-WT's ROE is -0.60%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, DNA-WT is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check ORKA's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, COGT has a market cap of 5.7B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while COGT trades at $33.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas COGT's P/E ratio is -15.83. In terms of profitability, DNA-WT's ROE is -0.60%, compared to COGT's ROE of -0.73%. Regarding short-term risk, DNA-WT is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check COGT's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, XENE has a market cap of 5.6B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while XENE trades at $58.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas XENE's P/E ratio is -12.38. In terms of profitability, DNA-WT's ROE is -0.60%, compared to XENE's ROE of -0.44%. Regarding short-term risk, DNA-WT is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check XENE's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, LGND has a market cap of 5.6B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while LGND trades at $280.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas LGND's P/E ratio is 30.81. In terms of profitability, DNA-WT's ROE is -0.60%, compared to LGND's ROE of +0.20%. Regarding short-term risk, DNA-WT is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check LGND's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas CDTX's P/E ratio is -19.77. In terms of profitability, DNA-WT's ROE is -0.60%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, DNA-WT is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check CDTX's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ERAS has a market cap of 5.6B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ERAS trades at $16.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas ERAS's P/E ratio is -17.38. In terms of profitability, DNA-WT's ROE is -0.60%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, DNA-WT is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check ERAS's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while PTCT trades at $66.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas PTCT's P/E ratio is -28.53. In terms of profitability, DNA-WT's ROE is -0.60%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, DNA-WT is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check PTCT's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, DNA-WT's ROE is -0.60%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, DNA-WT is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check ABCM's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas ISEE's P/E ratio is -22.44. In terms of profitability, DNA-WT's ROE is -0.60%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, DNA-WT is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check ISEE's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, DFTX has a market cap of 5.3B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while DFTX trades at $40.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas DFTX's P/E ratio is N/A. In terms of profitability, DNA-WT's ROE is -0.60%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, DNA-WT is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check DFTX's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas APLS's P/E ratio is 38.35. In terms of profitability, DNA-WT's ROE is -0.60%, compared to APLS's ROE of +0.40%. Regarding short-term risk, DNA-WT is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check APLS's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while CRSP trades at $52.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas CRSP's P/E ratio is -11.13. In terms of profitability, DNA-WT's ROE is -0.60%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, DNA-WT is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check CRSP's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while EWTX trades at $44.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas EWTX's P/E ratio is -24.12. In terms of profitability, DNA-WT's ROE is -0.60%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, DNA-WT is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check EWTX's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas TERN's P/E ratio is -51.41. In terms of profitability, DNA-WT's ROE is -0.60%, compared to TERN's ROE of -0.20%. Regarding short-term risk, DNA-WT is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check TERN's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ACAD has a market cap of 4.7B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ACAD trades at $27.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas ACAD's P/E ratio is 12.40. In terms of profitability, DNA-WT's ROE is -0.60%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, DNA-WT is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check ACAD's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas FOLD's P/E ratio is -161.00. In terms of profitability, DNA-WT's ROE is -0.60%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, DNA-WT is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check FOLD's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas AKRO's P/E ratio is -14.57. In terms of profitability, DNA-WT's ROE is -0.60%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, DNA-WT is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check AKRO's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas ALPN's P/E ratio is -101.52. In terms of profitability, DNA-WT's ROE is -0.60%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, DNA-WT is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check ALPN's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, MANE has a market cap of 4.2B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while MANE trades at $101.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas MANE's P/E ratio is -32.36. In terms of profitability, DNA-WT's ROE is -0.60%, compared to MANE's ROE of -0.38%. Regarding short-term risk, DNA-WT is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check MANE's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas OPT's P/E ratio is -1.52. In terms of profitability, DNA-WT's ROE is -0.60%, compared to OPT's ROE of +1.18%. Regarding short-term risk, DNA-WT is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check OPT's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while PRTC trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas PRTC's P/E ratio is -3.78. In terms of profitability, DNA-WT's ROE is -0.60%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, DNA-WT is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check PRTC's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, PBLS has a market cap of 4.2B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while PBLS trades at $36.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas PBLS's P/E ratio is -41.09. In terms of profitability, DNA-WT's ROE is -0.60%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, DNA-WT is more volatile compared to PBLS. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check PBLS's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RLAY has a market cap of 4.2B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while RLAY trades at $19.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas RLAY's P/E ratio is -12.14. In terms of profitability, DNA-WT's ROE is -0.60%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, DNA-WT is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check RLAY's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, IOVA has a market cap of 4.1B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while IOVA trades at $9.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas IOVA's P/E ratio is -12.68. In terms of profitability, DNA-WT's ROE is -0.60%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, DNA-WT is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check IOVA's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas MRTX's P/E ratio is -4.82. In terms of profitability, DNA-WT's ROE is -0.60%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, DNA-WT is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check MRTX's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CELC has a market cap of 4.1B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while CELC trades at $83.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas CELC's P/E ratio is -19.43. In terms of profitability, DNA-WT's ROE is -0.60%, compared to CELC's ROE of -3.51%. Regarding short-term risk, DNA-WT is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check CELC's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, TNGX has a market cap of 4B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while TNGX trades at $24.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas TNGX's P/E ratio is -29.57. In terms of profitability, DNA-WT's ROE is -0.60%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, DNA-WT is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check TNGX's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, TLX has a market cap of 4B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while TLX trades at $11.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas TLX's P/E ratio is 122.96. In terms of profitability, DNA-WT's ROE is -0.60%, compared to TLX's ROE of +0.07%. Regarding short-term risk, DNA-WT is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check TLX's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ADPT has a market cap of 4B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ADPT trades at $24.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas ADPT's P/E ratio is -60.44. In terms of profitability, DNA-WT's ROE is -0.60%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, DNA-WT is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check ADPT's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ELVN has a market cap of 3.9B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while ELVN trades at $54.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas ELVN's P/E ratio is -32.59. In terms of profitability, DNA-WT's ROE is -0.60%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, DNA-WT is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check ELVN's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas CPRX's P/E ratio is 12.30. In terms of profitability, DNA-WT's ROE is -0.60%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, DNA-WT is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check CPRX's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas RYZB's P/E ratio is -57.86. In terms of profitability, DNA-WT's ROE is -0.60%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, DNA-WT is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check RYZB's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, AMLX has a market cap of 3.7B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while AMLX trades at $33.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas AMLX's P/E ratio is -22.43. In terms of profitability, DNA-WT's ROE is -0.60%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, DNA-WT is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for DNA-WT.Check AMLX's competition here

Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, DNA-WT is priced at $0.27 on the NYSE, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA-WT currently has a P/E ratio of N/A, whereas CBAY's P/E ratio is -32.81. In terms of profitability, DNA-WT's ROE is -0.60%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, DNA-WT is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for DNA-WT.Check CBAY's competition here